- 06/01/2017
- initiatives for developing new medicines for neglected tropical diseases and malaria
- 04/19/2017
- eisai (china)’s total 1.98 million rmb worth of medicine donation to "health to countryside" activity for four consecutive years
- 04/11/2017
- speedy care to relieve fatigue! eisai to launch "chocola bb® gold rich"highest combination of active ingredients in chocola bb series. easy to drink bergamot flavor
- 04/05/2017
- eisai and meiji enter into licensing agreement concerning parkinson’s disease drug safinamide in japan and asia
- 04/05/2017
- eisai presents data of mechanisms of action relating to tumor immune response regarding combination of anticancer agent lenvatinib with anti-pd-1 antibody at aacr 108th annual meeting
- 03/28/2017
- german federal joint committee (g-ba) confirms additional benefit of anticancer agent kisplyx® (lenvatinib mesylate) in treatment of advanced renal cell carcinoma
- 02/16/2017
- eisai enters into marketing and distribution agreement with orion concerning parkinson’s disease drugs in china
- 01/05/2017
- eisai acquires all global development and marketing rights for chronic weight management treatment lorcaserin
- 12/19/2016
- anticancer agent treakisym® approved in japan for additional indication as first-line treatment for low-grade b-cell non-hodgkin′s lymphoma and mantle cell lymphoma
- 12/12/2016
- interim analysis of phase ib/ii study of eribulin and pembrolizumab combination regimen in metastatic triple negative breast cancer presented at san antonio breast cancer symposium
